KaydedilenlerDerginizi ekleyin

Dergiler / European Journal of Therapeutics / 2020 / Cilt: 26 - Sayı: 2

Role of Serum HMGB1 in Prostate Cancer

Hülya ÇİÇEK
Mehmet SOLAKHAN
Özlem Nuray SEVER
Mustafa YILDIRIM
Necla BENLİER
Zeliha YILDIRIM
Nuri ORHAN
Sayfa
108–112
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Significant difference was detected between the three groups (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Purpose: In our study the diagnostic role of HMGB1 levels measured in serum were investigated in prostatitis and prostate carcinoma diagnosis and in the differential diagnosis of these two diseases.
📊
Temel Bulgular & Veri:Material Method: Patients followed up for histopathologically verified diagnosis of prostate carcinoma and prostatitis in 20142017 at the Urology Clinic were included.
💡
Sonuç & Katkı:Significant difference was detected between the three groups (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Purpose: In our study the diagnostic role of HMGB1 levels measured in serum were investigated in prostatitis and prostate carcinoma diagnosis and in the differential diagnosis of these two diseases. Material Method: Patients followed up for histopathologically verified diagnosis of prostate carcinoma and prostatitis in 20142017 at the Urology Clinic were included. HMGB1 measurement in serum was performed with the ELISA method. Results: A total of 78 subjects were included in the study, consisting of 30 (38.5%) prostatitis patients, 25 (32%) prostate carcinoma patients and 23 (29.5%) healthy subjects. HMGB1 was detected as 11.9±2.6 (Range 6.7-18.4) ng/ml in the prostatitis group, 15.1±4.5 (Range 8.4-24.8) ng/ml in the prostate carcinoma patients and as 9.2±3.1 (Range 4.7-18.7) ng/ml in the control group. The difference between the groups were investigated using the Friedman test as HMGB1 did not show normal distribution. Significant difference was detected between the three groups (p

🔖

Bu Makaleye Atıf Yap

ÇİÇEK, H., SOLAKHAN, M., SEVER, Ö. N., YILDIRIM, M., BENLİER, N., YILDIRIM, Z., ORHAN, N. (2022). Role of Serum HMGB1 in Prostate Cancer. European Journal of Therapeutics, Cilt: 26 - Sayı: 2, 108–112. https://ajindex.com/articles/512187

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (5)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018 Jan; 68(1):7-30.
  2. Mohler JL, Antonarakis ES. NCCN Guidelines Updates: Management of Prostate Cancer. J Natl Compr Canc Netw. 2019 May 1;17(5.5):583586. doi: 10.6004/jnccn.2019.5011. Kappen S, Jürgens V, Freitag MH, Winter A. Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists. Cancer Manag Res. 2019 Apr 16;11:3079-3097. doi: 10.2147/CMAR.S193325. Kogan MI, Naboka YL, Ismailov RS, Belousov II, Gudima IA. Bacterial prostatitis: epidemiology and etiology. Urologiia. 2018 Dec;(6):144-148.
  3. Decaestecker K, Oosterlinck W. Transurethral resection of the prostate in recurrent acute bacterial prostatitis. Urol Int 2015; 94: 442444. Zhang J, McCauley MJ, Maher LJ 3rd, Williams MC, Israeloff NE. Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic Acids Res. 2009;37:1107-14.
  4. Vijayakumar EC, Bhatt LK, Prabhavalkar KS. High Mobility Group Box-1 (HMGB1): A potential target in therapeutics. Curr Drug Targets. 2019 Jun 18. doi: 10.2174/1389450120666190618125100. Kargı A, Demirpençe Ö, Gündüz Ş, Göktaş S, Alikanoğlu AS, Yıldırım M levels of HMGB1 have a diagnostic role in metastatic renal cell cancer. Cancer Biomarkers 17 (2016) 17–20.
  5. Neupane S, Steyerberg E, Raitanen J, Talala K, Pylväläinen J, Taari K, Tammela TL, Auvinen A. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial. Int J Urol. 2017 Dec 10. doi: 10.1111/iju.13508. 10. Gandaglia G, Albers P, Abrahamsson PA, Briganti A, Catto JWF, Chapple CR, Montorsi F, Mottet N, Roobol MJ, Sønksen J, Wirth M, van Poppel H. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. Eur Urol. 2019 May 12. pii: S0302-2838(19)30347-1. doi: 10.1016/j.eururo.2019.04.033. 11. Buddingh KT, Maatje MGF, Putter H, Kropman RF, Pelger RCM. Do antibiotics decrease prostate-specific antigen levels and reduce the need for prostate biopsy in type IV prostatitis? A systematic literature review. Can Urol Assoc J. 2018 Jan;12(1):E25-E30. doi: 10.5489/ cuaj.4515. 12. Cámara-Quílez M, Barreiro-Alonso A, Rodríguez-Bemonte E, Quindós-Varela M, Cerdán E, Lamas-Maceiras M. Differential characteristics of HMGB2 versus HMGB1 and their per-spectives in ovary and prostate cancer. Curr Med Chem. 2019 Jan 23. doi: 10.2174/092 9867326666190123120338. 13. Tripathi A, Shrin